Compare IART & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | DRTS |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | 2021 |
| Metric | IART | DRTS |
|---|---|---|
| Price | $18.18 | $14.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $14.33 | $8.67 |
| AVG Volume (30 Days) | ★ 925.0K | 569.0K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.39 | N/A |
| Revenue Next Year | $3.40 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.70 | $3.01 |
| 52 Week High | $20.49 | $14.75 |
| Indicator | IART | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 65.43 |
| Support Level | $16.53 | $6.59 |
| Resistance Level | $18.92 | N/A |
| Average True Range (ATR) | 0.98 | 0.76 |
| MACD | -0.07 | 0.15 |
| Stochastic Oscillator | 47.42 | 93.93 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.